-+ 0.00%
-+ 0.00%
-+ 0.00%

Aprea to present early Phase 1 data for WEE1 inhibitor APR-1051 at ASCO 2026

PUBT·04/21/2026 14:15:17
Listen to the news
Aprea to present early Phase 1 data for WEE1 inhibitor APR-1051 at ASCO 2026
  • Aprea Therapeutics set a clinical update for ACESOT-1051, a first-in-human Phase 1 trial of WEE1 inhibitor APR-1051 in advanced solid tumors, at ASCO 2026.
  • Initial trial results will be presented in a poster session on May 30, 2026, during ASCO Annual Meeting in Chicago.
  • Disclosure signals early readout from APR-1051 development program, a key catalyst for assessing clinical viability in biomarker-defined oncology.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604211015PRIMZONEFULLFEED9694005) on April 21, 2026, and is solely responsible for the information contained therein.